Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 805-813

  Harisi, Revekka ^a   Dudás, József ^a   Tímár, Ferenc ^a   Pogány, Gábor ^a   Paku, Sándor ^a   Tímár, József ^a   Kovalszky, Ilona ^a   Szendroi, Miklós ^a   Jeney, András ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

1 integrin; Doxorubicin; Extracellular matrix; Matrix metalloproteinase; Migration; Osteosarcoma; Proliferation; Topoisomerase II

Indexed keywords

BETA1 INTEGRIN; DOXORUBICIN; GELATINASE B;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL COMPARTMENTALIZATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MEGADOSE; ENZYME ANALYSIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LOW DRUG DOSE; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPARATION TECHNIQUE; THREE DIMENSIONAL IMAGING; TUMOR GROWTH;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD29; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; OSTEOSARCOMA;

EID: 17444427131     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Cox G and O'Byrne KJ: Matrix metalloproteinases and cancer. Anticancer Res 21: 4207-4219, 2001.
2. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas. Anticancer Res 21: 2021-2028, 2001.
3. Morell-Quadreny L, Rubio J, Lopez-Guerrero JA, Casanova J, Ramos D, Iborra I, Solsona E and Llombart-Bosch A: Disruption of basement membrane, extracellular matrix metalloproteinases and E-cadherin in renal-cell carcinoma. Anticancer Res 23: 5005-5010, 2003.
4. Jussila T, Kauppila S, Risteli L, Risteli J and Stenback F: Collagen formation in extracellular matrix of transplants of human transformed keratinocyte cell lines. Anticancer Res 22: 1705-1711, 2002.
5. Hagedorn HG, Tubel J, Wiest I, Schleicher ED and Nerlich AG: Prognostic aspects of the loss of epithelial basement membrane components in preinvasive and invasive laryngeal carcinomas. Anticancer Res 18: 201-207, 1998.
6. Dumas V, Kanitakis J, Charvat S, Euvrard S, Faute M and Claudy A: Expression of basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous basal and squamous cell carcinomas. Anticancer Res 19: 2929-2938, 1999.
7. Rossi M, Rooprai HK, Maidment SL, Rucklidge GJ amd Pilkington GJ: The influence of sequential, in vivo passage on secretion of matrix metalloproteinases by human brain tumour cells. Anticancer Res 16: 121-128, 1996.
8. Matsuoka T, Yashiro M, Sawada T, Ishikawa T, Ohira M and Chung KH: Inhibition of invasion and lymph node metastasis of gastrointestinal cancer cells by R-94138, a matrix metalloproteinase inhibitor. Anticancer Res 20: 4331-8, 2000.
9. Thorns V, Walter GF and Thorns C: Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res 23: 3937-3944, 2003.
10. Davies CD, Muller H, Hagen I, Garseth M and Hjelstuen MH: Comparison of extracellular matrix in human osteosarcomas and melanomas growing as xenografts, multicellular spheroids, and monolayer cultures. Anticancer Res 17: 4317-26, 1997.
11. Kawashima A, Nakanishi I, Tsuchiya H, Roessner A, Obata K and Okada Y: Expression of matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) induced by tumour necrosis factor alpha correlates with metastatic ability in a human osteosarcoma cell line. Virchows Arch 424: 547-552, 1994.
12. Minamitani K: Establishment of an osteoblastic osteosarcoma cell line and effects of cell culture conditions on secretion of matrix metalloproteinases from the cultured osteosarcoma cells. Kurume Med J 47: 115-124, 2000.
13. Fuks Z, Vlodavsky I, Andreeff M, McLoughlin M and Haimovitz-Friedman A: Effects of extracellular matrix on the response of endothelial cells to radiation in vivo. Eur J Cancer 28A: 725-731, 1992.
14. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature 411: 375-379, 2001.
15. Kouniavsky G, Khaikin M, Zvibel I, Zippel D, Brill S, Halpern Z and Papa M: Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin Exp Metastasis 19: 55-60, 2002.
16. Pogány G, Timár F, Oláh J, Harisi R, Polony G, Paku S, Bocsi J, Jeney A and Laurie GW: Role of the basement membrane in tumour cell dormancy and cytotoxic resistance. Oncology 60: 274-281, 2001.
17. Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S and Yamamoto N: Caffeine-assisted chemotherapy and minimized tumour excision for nonmetastatic osteosarcoma. Anticancer Res 18: 657-66, 1998.
18. Rintoul RC and Sethi T: Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 102: 417-24, 2002.
19. Bissell DM, Arenson DM, Mahel JJ and Roll FJ: Support of cultured hepatocytes by a laminin-rich gel. J Clin Invest 79: 801-812, 1987.
20. Kleinman HK, McGarvey MJ, Liotta LA, Robey PG, Tryggvason K and Martin GR: Isolation and characterization of type IV procollagen, laminin, heparan sulfate proteoglycan from EHS sarcoma. Biochemistry 21: 6188-6193, 1982.
21. Kramer RH, Bensch KG and Wong J: Invasion of reconstituted basement membrane matrix by metastatic human tumour cells. Cancer Res 46: 1980-1989, 1986.
22. Babo I, Bocsi J and Jeney A: The site-dependent growth characteristics of a human xenotransplanted basaloid squamous cell carcinoma. J Cancer Res Clin Oncol 125: 35-41, 1999.
23. Heussen C and Dowdle EB: Electrophoretic analysis plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102: 196-202, 1980.
24. Yamagata S, Ito Y, Tanaka R and Shimizu S: Gelatinases of metastatic cell lines of murine colonic carcinoma as detected by substrate-gel electrophoresis. Biochem Biophys Res Commun 151: 158-162, 1998.
25. Dignam JD, Lebovitz RM and Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489, 1983.
26. Marini JC, Miller KG and Englund PT: Decatenation of kinetoplast DNA by topoisomerases. J Biol Chem 255: 4976-4979, 1980.
27. Riou JF, Fosse P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, Saucier JM, Bisagni E and Lavelle F: Intoplicine (RP 60475) and its derivates, a new class of antitumour agents inhibiting both topoisomerase I and II activities. Cancer Res 53: 5987-5993, 1993.
28. Bissell DM and Radinsky D: Putting tumours in context. Nature Rev Cancer 1: 46-54, 2001.
29. Lukashev ME and Werb Z: ECM signalling orchestrating cell behaviour and misbehaviour. Trends Cell Biol 8: 437-441, 1998.
30. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield J, Donnelly SC, Strieter R and Haslett C: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Med 5: 662-668, 1999.
31. Timar J, Pogany G, Balazs M, Szollosi J, Ladanyi A, Olah J, Timar F, Lapis K and Jeney A: Modulation of membrane phenotype, matrix adhesion and microinvasiveness of metastatic tumour cells by HudR. Cell Biochem Funct 8: 211-220, 1990.
32. Mueller MM and Fusenig NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4: 839-49, 2004.
33. Berger SJ, Gupta S, Belfi CA, Gosky DM and Mukhtar H: Green tea constituent (-)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells. Biochem Biophys Res Commun 288: 101-105, 2001.
34. Hashimoto S, Chatterjee S, Ranjit GB, Bao C, Ford J, Ganapathi R, Berger SJ and Berger NA: Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth. Oncol Res 7: 407-416, 1995.
35. Boege F: Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects. Eur J Clin Chem Clin Biochem 34: 873-888, 1996.